Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDO2 | P48775 | 4/20 | 0.59 |
| ▸ | IDO1 | P14902 | 19/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17665347 | 0.88 | TDO2 (0.56) | TDO2IDO1 | |
| SCHEMBL17665358 | 0.83 | TDO2 (0.56) | TDO2IDO1 | |
| SCHEMBL16135394 | 0.82 | TDO2 (0.56) | TDO2IDO1CYP3A4 | |
| SCHEMBL20129574 | 0.82 | TDO2 (0.64) | TDO2IDO1CYP3A4CYP2D6CYP2B6 | |
| SCHEMBL16135434 | 0.81 | TDO2 (0.56) | TDO2IDO1 | |
| SCHEMBL16135339 | 0.80 | TDO2 (0.55) | TDO2IDO1 | |
| SCHEMBL16135440 | 0.78 | TDO2 (0.53) | TDO2IDO1 | |
| SCHEMBL16135397 | 0.77 | IDO1 (0.60) | TDO2IDO1CYP3A4CYP2D6CYP2B6 | |
| SCHEMBL16135387 | 0.76 | TDO2 (0.51) | TDO2IDO1 | |
| SCHEMBL17665331 | 0.76 | IDO1 (0.61) | TDO2IDO1CYP3A4CYP2D6CYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3366678-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF IMMUNOSUPPRESSION MEDIATED BY TRYPTOPHAN METABOLIZATION | Newlink Genetics Corporation (US) | 2018-08-29 | — | — | EP | claimed |
| US-9981973-B2 | Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization | NEWLINK GENETICS CORPORATION (US) | 2018-05-29 | — | — | US | claimed |
| EP-2976332-B1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF IMMUNOSUPPRESSION MEDIATED BY TRYPTOPHAN METABOLIZATION. | NEWLINK GENETICS CORP (US) | 2018-01-31 | — | — | EP | claimed |
| US-20170260188-A1 | Tricyclic Compounds as Inhibitors of Immunosuppression Mediated By Tryptophan Metabolization | NEWLINK GENETICS CORPORATION | 2017-09-14 | — | — | US | claimed |
| US-9617272-B2 | Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization | NEWLINK GENETICS CORPORATION (US) | 2017-04-11 | — | — | US | claimed |
| EP-3366678-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF IMMUNOSUPPRESSION MEDIATED BY TRYPTOPHAN METABOLIZATION | Newlink Genetics Corporation (US) | 2018-08-29 | — | — | EP | disclosed |
| US-9981973-B2 | Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization | NEWLINK GENETICS CORPORATION (US) | 2018-05-29 | — | — | US | disclosed |
| US-9981973-B2 | Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization | NEWLINK GENETICS CORPORATION (US) | 2018-05-29 | — | — | US | disclosed |
| US-9981973-B2 | Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization | NEWLINK GENETICS CORPORATION (US) | 2018-05-29 | — | — | US | disclosed |
| EP-2976332-B1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF IMMUNOSUPPRESSION MEDIATED BY TRYPTOPHAN METABOLIZATION. | NEWLINK GENETICS CORP (US) | 2018-01-31 | — | — | EP | disclosed |
| EP-2976332-B1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF IMMUNOSUPPRESSION MEDIATED BY TRYPTOPHAN METABOLIZATION. | NEWLINK GENETICS CORP (US) | 2018-01-31 | — | — | EP | disclosed |
| US-20170260188-A1 | Tricyclic Compounds as Inhibitors of Immunosuppression Mediated By Tryptophan Metabolization | NEWLINK GENETICS CORPORATION | 2017-09-14 | — | — | US | disclosed |
| US-9617272-B2 | Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization | NEWLINK GENETICS CORPORATION (US) | 2017-04-11 | — | — | US | disclosed |
| US-9617272-B2 | Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization | NEWLINK GENETICS CORPORATION (US) | 2017-04-11 | — | — | US | disclosed |
| US-9617272-B2 | Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization | NEWLINK GENETICS CORPORATION (US) | 2017-04-11 | — | — | US | disclosed |
| WO-2016051181-A1 | 4H-IMIDAZO[1,5-A]INDOLE DERIVATIVES AND THEIR USE AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) AND/OR TRYPTOPHAN 2,3-DIOXYGENASE (TD02) MODULATORS | REDX PHARMA PLC (GB) | 2016-04-07 | — | — | WO | disclosed |
| US-20160060266-A1 | Tricyclic Compounds as Inhibitors of Immunosuppression Mediated By Tryptophan Metabolization | NEWLINK GENETICS CORPORATION | 2016-03-03 | — | — | US | disclosed |
| US-20160060266-A1 | Tricyclic Compounds as Inhibitors of Immunosuppression Mediated By Tryptophan Metabolization | NEWLINK GENETICS CORPORATION | 2016-03-03 | — | — | US | disclosed |
| US-20160060266-A1 | Tricyclic Compounds as Inhibitors of Immunosuppression Mediated By Tryptophan Metabolization | NEWLINK GENETICS CORPORATION | 2016-03-03 | — | — | US | disclosed |
| WO-2014159248-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF IMMUNOSUPPRESSION MEDIATED BY TRYPTOPHAN METABOLIZATION | NEWLINK GENETICS CORPORATION (US) | 2014-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170260188-A1 | Tricyclic Compounds as Inhibitors of Immunosuppression Mediated By Tryptophan Metabolization | IDO1, IDO2, TDO2 | TDO2 3/4885IDO1 1/4885CYP3A4 142/4885 |
| US-20160060266-A1 | Tricyclic Compounds as Inhibitors of Immunosuppression Mediated By Tryptophan Metabolization | IDO1, IDO2, TDO2 | TDO2 3/4885IDO1 1/4885CYP3A4 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.